Literature DB >> 21207025

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Michael S Leibowitz1, Pedro A Andrade Filho, Soldano Ferrone, Robert L Ferris.   

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) cells can escape recognition by tumor antigen (TA)-specific cytotoxic T lymphocytes (CTL) by downregulation of antigen processing machinery (APM) components, such as the transporter associated with antigen processing (TAP)-1/2 heterodimer. APM component upregulation by interferon gamma (IFN-γ) restores SCCHN cell recognition and susceptibility to lysis by CTL, but the mechanism underlying TAP1/2 downregulation in SCCHN cells is not known. Because IFN-γ activates signal transducer and activator of transcription (STAT)-1, we investigated phosphorylated (p)-STAT1 as a mediator of low basal TAP1/2 expression in SCCHN cells. SCCHN cells were found to express basal total STAT1 but low to undetectable levels of activated STAT1. The association of increased pSTAT1 levels and APM components likely reflects a cause-effect relationship, since STAT1 knockdown significantly reduced both IFN-γ-mediated APM component expression and TA-specific CTL recognition of IFN-γ-treated SCCHN cells. On the other hand, since oncogenic pSTAT3 is overexpressed in SCCHN cells and was found to heterodimerize with pSTAT1, we also tested whether pSTAT3 and pSTAT1:pSTAT3 heterodimers inhibited IFN-γ-induced STAT1 activation and APM component expression. First, STAT3 activation or depletion did not affect basal or IFN-γ-induced expression of pSTAT1 and APM components or recognition of SCCHN cells by TA-specific CTL. Second, pSTAT1:pSTAT3 heterodimers did not interfere with IFN-γ-induced STAT1 binding to the TAP1 promoter or APM protein expression. These findings demonstrate that APM component downregulation is regulated primarily by an IFN-γ-pSTAT1-mediated signaling pathway, independent of oncogenic STAT3 overexpression in SCCHN cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207025      PMCID: PMC3426276          DOI: 10.1007/s00262-010-0961-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  45 in total

Review 1.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies.

Authors:  N Bandoh; T Ogino; H S Cho; S Y Hur; J Shen; X Wang; S Kato; N Miyokawa; Y Harabuchi; S Ferrone
Journal:  Tissue Antigens       Date:  2005-09

3.  Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.

Authors:  Andreas Albers; Koji Abe; Jennifer Hunt; Jun Wang; Andres Lopez-Albaitero; Carsten Schaefer; William Gooding; Theresa L Whiteside; Soldano Ferrone; Albert DeLeo; Robert L Ferris
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 4.  Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.

Authors:  Robert L Ferris; Theresa L Whiteside; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

5.  IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity.

Authors:  Marie-Christine Rouyez; Marta Lestingi; Martine Charon; Serge Fichelson; Agnès Buzyn; Isabelle Dusanter-Fourt
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

6.  Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Authors:  Z Chen; P S Malhotra; G R Thomas; F G Ondrey; D C Duffey; C W Smith; I Enamorado; N T Yeh; G S Kroog; S Rudy; L McCullagh; S Mousa; M Quezado; L L Herscher; C Van Waes
Journal:  Clin Cancer Res       Date:  1999-06       Impact factor: 12.531

7.  Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation.

Authors:  Hao H Ho; Lionel B Ivashkiv
Journal:  J Biol Chem       Date:  2006-03-29       Impact factor: 5.157

8.  Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.

Authors:  A Francesca Setiadi; Muriel D David; Susan S Chen; John Hiscott; Wilfred A Jefferies
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

9.  Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

Authors:  Andrés López-Albaitero; Jayakar V Nayak; Takeshi Ogino; Avinash Machandia; William Gooding; Albert B DeLeo; Soldano Ferrone; Robert L Ferris
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

10.  The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.

Authors:  T Hayashi; Y Kobayashi; S Kohsaka; K Sano
Journal:  Oncogene       Date:  2006-02-13       Impact factor: 9.867

View more
  45 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

2.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 3.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 4.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

5.  STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Authors:  Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Jie Hyun-Bae; Lin Wang; Raja R Seethala; Barton F Branstetter; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2015-05-13       Impact factor: 11.151

Review 6.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

7.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

8.  TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.

Authors:  Agnes Ling; Anna Löfgren-Burström; Pär Larsson; Xingru Li; Maria L Wikberg; Åke Öberg; Roger Stenling; Sofia Edin; Richard Palmqvist
Journal:  Oncoimmunology       Date:  2017-08-07       Impact factor: 8.110

9.  STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.

Authors:  Nicole C Schmitt; Sumita Trivedi; Robert L Ferris
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

Review 10.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Authors:  Jessica L Geiger; Jennifer R Grandis; Julie E Bauman
Journal:  Oral Oncol       Date:  2015-12-28       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.